ASX Announcements Archive 2012
17 Dec 2012
Change of Director’s Interest Notice
11 Dec 2012
Open Briefing interview with MD & CEO Robert Klupacs
21 Nov 2012
Change of Director's Interest Notice
21 Nov 2012
Appendix 3B
20 Nov 2012
Results of Annual General Meeting 20 November 2012
20 Nov 2012
CEO AGM Presentation to shareholders
20 Nov 2012
Chairman's Address to Shareholders
20 Nov 2012
CEO AGM Presentation to Shareholders
15 Nov 2012
Circadian grants world-wide licence to Bio-Rad to market research products
08 Nov 2012
VGX-100 Poster Presentation at EORTC
08 Nov 2012
VGX-100 Poster Presentation at EORTC
07 Nov 2012
VGX-100 Top 10 Oncology Candidate Windhover Conference
02 Nov 2012
AusBiotech Presentation Company Update
22 Oct 2012
Annual Report / Notice of AGM and Proxy
02 Oct 2012
Dr Errol Malta – Resignation as Director
24 Sep 2012
Open Briefing - FY2012 Results and Outlook
24 Aug 2012
Appendix 3B
24 Aug 2012
Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)
23 Aug 2012
Preliminary Final Report (Appendix 4E) - Financial Year Ended 30 June 2012
17 Jul 2012
Update to Substantial Holding Notice for Antisense Therapeutics Limited
12 Jul 2012
Change of Director’s Interest Notice
10 Jul 2012
Change of Director’s Interest Notice
09 Jul 2012
Alpha Securities Analyst Investment Research Report Available on Circadian Website
07 Jul 2012
Bio 2012 - Building a Diagnostics Franchise
27 Jun 2012
Commercial Launch of CUP Test
22 Jun 2012
Appendix 3B
22 Jun 2012
Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth)
12 Jun 2012
Circadian makes $1M Share Placement
12 Jun 2012
Reinstatement to Official Quotation
07 Jun 2012
Suspension Confirm
07 Jun 2012
Suspension Request
05 Jun 2012
Request for Trading Halt
01 Jun 2012
Updated Corporate Presentation
16 May 2012
Appendix 3B
27 Apr 2012
Notice of Ceasing to be a Substantial Holder
02 Apr 2012
Change of Director’s Interest Notice
29 Mar 2012
Update to Substantial Holding Notice for Antisense Therapeutics Limited
15 Mar 2012
Analyst Investment Research Report Available on Circadian Website
09 Mar 2012
Positive data published on performance of Circadian’s Cancers of Unknown Primary Diagnostic Test
09 Mar 2012
Development of a Gene Expression Based Assay to Determine the Origin of Metastatic Carcinomas of...
20 Feb 2012
Open Briefing with CEO & MD Robert Klupacs - Half Year Results and Outlook
16 Feb 2012
Half-Year Financial Report & Operational Achievements
30 Jan 2012
VGX-100 identified as potential new therapy for improving corneal graft survival
12 Jan 2012
CEO Presentation at Biotech Showcase San Francisco
09 Jan 2012
Circadian commences first Phase 1 clinical trial of VEGF-C antibody VGX-100 in cancer patients